We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
1.Ignatowicz, L, Ignatowicz, R, Jozwiak, Ret al. Psychiatric aspects of epilepsy in childhood treated with Tegretol CR (Ciba-Geigy) (Abstr. of paper). Epilepsia (USA)1995;36(3):S128–S129.Google Scholar
2
2.De deyn Peter, Mol L, et al. An open multicenter prospective study of the effects of monotherapy with controlled-release carbamazepine on newly diagnosed generalized tonic&-clonic seizures. Seizure1994;3:235–238.Google Scholar
3
3.Eeg-Olofsson, O, Nilsson, H, Tonnby, B, et al. Diurnal variation of carbamazepine and carbamazepine-10,11- epoxide in plasma and saliva in children with epilepsy: A comparison between conventional and slow-release formulations. Jrnl Child Neurol (USA)1990;5(2):159–165.CrossRefGoogle ScholarPubMed
4
4.Tegretol® Product Monograph, November 1995.Google Scholar
5
5.Aldenkamp, et al. Controlled release carbamazepine: cognitive side effects in patients with epilepsy. Epilepsia1987;28(3):507–514.Google Scholar
6
6.Dhalla, Z, Bruni, J, Sutton, J. A comparison of the efficacy and tolerability of controlled-release carbamazepine. Cdn Jrnl Neurl Sciences1991;18:66–68.Google Scholar
7
7.Canger, R, Altamura, AC, Belvedere, O, Monaco, F, Monza, GCet al. Conventional vs controlled-release carbamazepine: a multicentre, double-blind, cross-over study. Acta Neurol Scand1990;82:9–13.Google Scholar